Biotage acquires Phynexus in $21.5m deal

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/PeopleImages)
(Image: Getty/PeopleImages)

Related tags: Chromatography, Robotics, Pipette, acquistion, downstream systems

Biotage will add PhyNexus’ platform for higher throughput purification at lab-scale.

Biotage’s acquisition of PhyNexus is expected to strengthen its positions as a separations company in the biomolecule arena.

Per the agreement, Biotage can provide an enabling automation platform to its global customers. The platform is based on dual flow chromatography and uses a patented tip technology for higher throughput purification of biomolecules at lab-scale.

Chromatography and attached platforms to strengthen chromatography units have been a recent addition to facilities across the biopharmaceutical industry as of late.

This testing service is in combination with high throughput pipetting robotics and its new media development program.

The acquisition will cost Biotage $21.5m (€18.8m). The company stated that it will finance the transaction through the issues of 487,337 new shares. The rest will be completed with ‘cash at hand’.

New shares will be issued to the main shareholders of PhyNexus and additional shares may be issued in connection with post-closing price adjustments and earn-out payments. The share and cash transaction is expected to be completed in January 2019.

GE Healthcare recently added a fiber-based purification​ platform to its chromatography portfolio. BIA Separations also expanded its manufacturing site​ to further enable its chromatographic products and increase its capabilities in upstream and downstream processing. 

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more